Hopefully BIEL issues a general PR like the following soon, followed by a series of PR's with details:
[Company Name] Signals a New Era in Precision Medicine with Expansion of its "Human Electrome" Bioelectronic Platform
CITY, STATE — February 10, 2026 — [Company Name], a leader in software-defined bioelectronics, today announced a major strategic pivot to accelerate the commercialization of its "Human Electrome" platform. By moving beyond traditional pain management, the company is positioning itself at the forefront of the bioelectronic medicine revolution, targeting a multi-indication pipeline that includes neuropathy, arthritis, and post-surgical recovery.
From Chemical Intervention to Bioelectronic Intelligence
For decades, medicine has relied on chemical compounds to treat systemic issues. [Company Name] is disrupting this paradigm by interfacing directly with the body’s endogenous electrical system—the Human Electrome. While the industry has historically focused on invasive implants, [Company Name] has successfully decoded the transdermal interface, delivering clinical-grade "bioelectric signatures" that trigger cellular-level repair without systemic side effects.
A Platform Built for the Future of Healthcare
"We are no longer just a medical device company; we are an electrome-sequencing company," said [Executive Name], CEO of [Company Name]. "By treating the body as a bio-digital system, we can provide precise, non-pharmacological interventions for some of the most burdensome chronic conditions of our time. We aren’t just blocking pain; we are recalibrating the electrical blueprint of human health."
Key Strategic Pillars for 2026:
Indication Expansion: The company is initiating new clinical protocols targeting Peripheral Neuropathy (improving neural signal-to-noise ratios), Chronic Arthritis (modulating inflammatory cytokines), and Post-Surgical Healing (accelerating the ‘Current of Injury’ for faster tissue synthesis).
The Electrome Narrative: Positioning the company’s proprietary waveform library as a vital asset alongside the Genome and Microbiome in the triad of modern precision medicine.
Software-as-a-Therapy (SaaT): Leveraging a digital-first approach where new therapeutic outcomes are unlocked via over-the-air (OTA) updates to existing hardware, providing an unparalleled moat in the medtech space.
Strengthening Investor & Scientific Partnerships
This shift aligns with the $27B+ global bioelectronic market, which is increasingly focused on non-invasive, data-driven solutions. [Company Name] is currently engaging with strategic partners and institutional investors to scale its research into "Electrome Mapping," a process that uses AI to refine patient-specific waveforms for optimized clinical outcomes.
About [Company Name]
[Company Name] is a bioelectronic medicine company dedicated to decoding the Human Electrome. Through its proprietary transdermal platform, the company delivers targeted electrical signaling to treat chronic disease and accelerate recovery. Based in [City, State], [Company Name] is bridging the gap between digital technology and biological healing.
Media Contact:
[Name]
[Title]
[Email]
[Phone Number]
[Company Name] Signals a New Era in Precision Medicine with Expansion of its "Human Electrome" Bioelectronic Platform
CITY, STATE — February 10, 2026 — [Company Name], a leader in software-defined bioelectronics, today announced a major strategic pivot to accelerate the commercialization of its "Human Electrome" platform. By moving beyond traditional pain management, the company is positioning itself at the forefront of the bioelectronic medicine revolution, targeting a multi-indication pipeline that includes neuropathy, arthritis, and post-surgical recovery.
From Chemical Intervention to Bioelectronic Intelligence
For decades, medicine has relied on chemical compounds to treat systemic issues. [Company Name] is disrupting this paradigm by interfacing directly with the body’s endogenous electrical system—the Human Electrome. While the industry has historically focused on invasive implants, [Company Name] has successfully decoded the transdermal interface, delivering clinical-grade "bioelectric signatures" that trigger cellular-level repair without systemic side effects.
A Platform Built for the Future of Healthcare
"We are no longer just a medical device company; we are an electrome-sequencing company," said [Executive Name], CEO of [Company Name]. "By treating the body as a bio-digital system, we can provide precise, non-pharmacological interventions for some of the most burdensome chronic conditions of our time. We aren’t just blocking pain; we are recalibrating the electrical blueprint of human health."
Key Strategic Pillars for 2026:
Indication Expansion: The company is initiating new clinical protocols targeting Peripheral Neuropathy (improving neural signal-to-noise ratios), Chronic Arthritis (modulating inflammatory cytokines), and Post-Surgical Healing (accelerating the ‘Current of Injury’ for faster tissue synthesis).
The Electrome Narrative: Positioning the company’s proprietary waveform library as a vital asset alongside the Genome and Microbiome in the triad of modern precision medicine.
Software-as-a-Therapy (SaaT): Leveraging a digital-first approach where new therapeutic outcomes are unlocked via over-the-air (OTA) updates to existing hardware, providing an unparalleled moat in the medtech space.
Strengthening Investor & Scientific Partnerships
This shift aligns with the $27B+ global bioelectronic market, which is increasingly focused on non-invasive, data-driven solutions. [Company Name] is currently engaging with strategic partners and institutional investors to scale its research into "Electrome Mapping," a process that uses AI to refine patient-specific waveforms for optimized clinical outcomes.
About [Company Name]
[Company Name] is a bioelectronic medicine company dedicated to decoding the Human Electrome. Through its proprietary transdermal platform, the company delivers targeted electrical signaling to treat chronic disease and accelerate recovery. Based in [City, State], [Company Name] is bridging the gap between digital technology and biological healing.
Media Contact:
[Name]
[Title]
[Email]
[Phone Number]
